摘要
目的评价肿瘤电场治疗同步放化疗方案用于治疗新诊断胶质母细胞瘤患者的安全性。方法回顾性分析南京医科大学第一附属医院神经外科自2022年2月至2022年11月收治的23例新诊断胶质母细胞瘤患者的临床资料。所有患者皆采取肿瘤电场治疗同步放化疗方案。按照常见不良事件通用术语5.0版标准(CTCAE 5.0)和肿瘤电场治疗相关皮肤不良反应(dAE)分级标准记录不良事件。治疗依从性通过Optume Nove TTF-200A治疗设备的使用数据进行评估,以每日肿瘤电场治疗使用时间的百分比计算。结果23例新诊断胶质母细胞瘤患者每日治疗中位时长为20.0 h,治疗依从性中位值为83.3%,dAE发生率为60.8%,主要为1级(56.5%)和2级(4.3%),无3~4级dAE。dAE主要表现为接触性皮炎、水泡、皮损等。21.7%(5/23)患者出现1~2级放化疗相关血液学不良反应,未发生严重血液系统疾病和重度电解质紊乱。结论新诊断胶质母细胞瘤术后采取肿瘤电场治疗同步放化疗方案是安全可靠的。
Objective To evaluate the safety of concurrent chemoradiation and tumor treating fields(TTFields)in patients with newly diagnosed glioblastoma.Methods The clinical data of 23 newly diagnosed glioblastoma patients who received concurrent chemoradiation and TTFields from February 2022 to November 2022 in the First Affiliated Hospital of Nanjing Medical University were analyzed retrospectively.All patients were treated with concurrent chemoradiation and TTfields.Common Terminology Criteria for adverse Events v5.0(CTCAE v5.0)and TTFields related to skin adverse reaction(dAE)criteria were used to evaluate the adverse events.Treatment compliance was evaluated by data on the use of T T Fields devices,and calculated as a percentage of daily TTFileds usage.Results The median duration of TTFields was 20.0 hours daily,with a median compliance rate of 83.3%.In general,the rate of common adverse events was 60.8%,including grade 1 dAE(56.5%)and grade 2 dAE(4.3%)manifested as contact dermatitis,blisters and skin lesion.No case with grade 3 or 4 dAE occurred.The rate of slight adverse relating to chemoradiation was 21.7%.There was no case of serious disease of the blood system and severe electrolyte abnormalities.Conclusions The treatment of concurrent chemoradiation and TTFields was safe and reliable.
作者
李金潭
陆泓宇
范啸
王协锋
陶超
颜伟
张军霞
LI Jintan;LU Hongyu;FAN Xiao;WANG Xiefeng;TAO Chao;YAN Wei;ZHANG Junxia(Department of Neurosurgery,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)
出处
《中国肿瘤外科杂志》
CAS
2023年第2期128-132,共5页
Chinese Journal of Surgical Oncology
作者简介
第一作者:李金潭,男,硕士研究生在读,研究方向:神经肿瘤临床研究,Email:lijintan2017@163.com;通信作者:张军霞,男,博士,副主任医师,副教授,研究方向:神经肿瘤临床与基础研究,Email:zjx2032@126.com。
